No Data
On December 4, Eurobio (01477.HK) spent HKD 0.079 million to repurchase 0.015 million shares.
Gelonghui reported on December 4 that OcuVision Biotech-B (01477.HK) announced it spent 0.079 million Hong Kong dollars to repurchase 0.015 million shares on December 4.
Ocumension Therapeutics Enrolls Patients for Second Phase 3 Trial of Glaucoma Drug
Eucan Vision Bio-B (01477.HK): The enrollment of patients for the second Phase III clinical trial of OT-301 in china has been completed.
Gelonghui December 3rd | Ocuvite Biosciences-B (01477.HK) announced that one of the group's main candidate drugs, OT-301 (NCX470) (being jointly developed by Nicox S.A. ("Nicox") and the group, is a novel nitric oxide (NO) donor-type bimatoprost analogue), has recently completed its second Phase III clinical trial in china ("Denali trial") with over 140 patients enrolled. The first Phase III clinical trial of NCX 470 (Mont Blanc trial) was conducted in June 2020 by
Eukon Vision Biotech-B (01477.HK) repurchased 1,500 shares on December 2.
Grainloong 2nd Dec. | Eucon Pharmaceuticals Group-B (01477.HK) announced that on 2nd Dec, it spent 7,820 Hong Kong dollars to repurchase 1,500 shares.
Eurocell Life Sciences-B (01477) repurchased 1000 shares on November 29th.
Ocuvision Biotech-B (01477) announced that the company spent 5,190... on November 29, 2024.
On November 27, 2023, Eucan Vision Biotech-B (01477.HK) spent 0.024 million Hong Kong dollars to repurchase 4,500 shares.
Gelonghui, November 27丨Eokunweishi Biology-B (01477.HK) announced that on November 27, it spent 0.024 million HKD to repurchase 4,500 shares.
Companies Like Ocumension Therapeutics (HKG:1477) Are In A Position To Invest In Growth
No Data
